News

What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in their portfolios with a new year starting, either.

Three Motley Fool

It's been an interesting year for the stock market. The broader benchmark S&P 500 (SNPINDEX: ^GSPC) blazed roughly 24.5% higher (as of Dec. 27), thanks largely to eight high-flying tech stocks with

Pfizer (NYSE: PFE) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market. The company generated billions of dollars in revenue thanks to its

Every investor has heard the phrase "buy low, sell high." It's a simple enough piece of advice that's less simple to apply. What exactly qualifies as "low"? One possible answer is when a company's

In today's video, I will be talking about the recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer

Artificial intelligence (AI) was the dominant theme in the stock market in 2024. There were standout performances from select AI chip stocks, AI software stocks, and even energy stocks, as

It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson

There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to

The demand for the chips required for training and deploying artificial intelligence (AI) models and applications in data centers increased at a remarkable pace in the past couple of years. Nvidia

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD) and other semiconductor stocks that long-term investors should keep on their watch lists. To learn more, check out the short video,

Rocket Lab (NASDAQ: RKLB) stock started Monday strong as its shares gained nearly 6% on news of a successful end-of-year rocket launch, putting another Synspective synthetic aperture radar (SAR)

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to offer

Multiple secular trends are happening to drive long-term growth for companies in the semiconductor sector. These trends include the rise of artificial intelligence (AI), expansion in edge computing

AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in

Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (NYSE: PFE) is communicating that

Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market.

Amidst an evolving field of competitors, the big pharma is committing

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called "Santa Claus rallies" can occur near

Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (NYSE: MRK).

Given that Viking

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (NASDAQ: VKTX) stock into something of a tailspin this week. According to data compiled by S&P Global Market

California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing

Bad news for Novo Nordisk (NYSE: NVO) Friday was good news for Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX), its two main rivals in the field of weight loss drugs. This morning, Novo